BridgeBio Pharma, Inc.
US ˙ NasdaqGS ˙ US10806X1028

Introduction

This page provides a comprehensive analysis of the known insider trading history of James C Momtazee. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate James C Momtazee has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ROIV / Roivant Sciences Ltd. Director 96,670
US:BBIO / BridgeBio Pharma, Inc. Director 95,080
LU:XAL5000DAC10 / ICON Luxembourg Sarl Director 0
US:MAAC / Montes Archimedes Acquisition Corp - Class A Chief Executive Officer, Director, 10% Owner 10,167,956
US:ENTL / Entellus Medical, Inc. Director 0
US:JAZZ / Jazz Pharmaceuticals plc Director 17,315
US:AIQ / Global X Funds - Global X Artificial Intelligence & Technology ETF Director 25,944,570
US:ACW / Accuride Corp Director 7,850,213
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by James C Momtazee. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases BBIO / BridgeBio Pharma, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BBIO / BridgeBio Pharma, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2021-12-29 BBIO MOMTAZEE JAMES C 80,000 14.5000 80,000 14.5000 1,160,000 5 17.1600 212,800 18.34

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BBIO / BridgeBio Pharma, Inc. Insider Trades
Insider Sales BBIO / BridgeBio Pharma, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BBIO / BridgeBio Pharma, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BBIO / BridgeBio Pharma, Inc. Insider Trades
Insider Purchases ROIV / Roivant Sciences Ltd. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BBIO / BridgeBio Pharma, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ROIV / Roivant Sciences Ltd. Insider Trades
Insider Sales ROIV / Roivant Sciences Ltd. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BBIO / BridgeBio Pharma, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ROIV / Roivant Sciences Ltd. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by James C Momtazee as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-07-21 2025-07-17 4 ROIV Roivant Sciences Ltd.
Common Shares
F - Taxes -241 96,670 -0.25 11.65 -2,808 1,126,206
2025-07-21 2025-07-17 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 1,201 96,911 1.25
2025-06-24 2025-06-20 4 BBIO BridgeBio Pharma, Inc.
Common Stock
A - Award 6,589 95,080 7.45
2025-04-21 2025-04-17 4 ROIV Roivant Sciences Ltd.
Common Shares
F - Taxes -276 95,710 -0.29 10.15 -2,801 971,456
2025-04-21 2025-04-17 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 1,379 95,986 1.46
2025-01-27 2025-01-23 4 ROIV Roivant Sciences Ltd.
Common Shares
F - Taxes -306 94,607 -0.32 11.21 -3,430 1,060,544
2025-01-27 2025-01-23 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 1,248 94,913 1.33
2024-10-23 2024-10-21 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 1,231 93,665 1.33
2024-09-16 2024-09-12 4 ROIV Roivant Sciences Ltd.
Common Shares
J - Other -3,056 92,434 -3.20 12.12 -37,039 1,120,300
2024-09-12 2024-09-10 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 16,406 95,490 20.75
2024-07-25 2024-07-23 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 1,555 79,091 2.01
2024-04-26 2024-04-24 4 ROIV Roivant Sciences Ltd.
Common Shares
F - Taxes -293 77,536 -0.38 10.90 -3,194 845,142
2024-04-26 2024-04-24 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 1,490 77,829 1.95
2024-01-23 2024-01-19 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 1,570 76,339 2.10
2023-10-18 2023-10-17 4 ROIV Roivant Sciences Ltd.
Common Shares
J - Other X -687 74,769 -0.91 10.30 -7,076 770,121
2023-10-18 2022-10-16 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 1,594 75,456 2.16
2023-09-20 2023-09-18 4 ROIV Roivant Sciences Ltd.
Common Shares
J - Other X -6,752 73,862 -8.38 11.17 -75,420 825,039
2023-09-14 2023-09-12 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 17,825 80,614 28.39
2023-07-06 2023-07-03 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 1,664 62,789 2.72
2023-04-05 2023-04-03 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 1,351 61,125 2.26
2023-01-05 2023-01-03 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 2,447 59,774 4.27
2022-11-02 2022-10-31 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 3,404 57,327 6.31
2022-09-19 2022-09-15 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 50,000 53,923 1,274.53
2022-07-25 2022-07-20 4 ROIV Roivant Sciences Ltd.
Common Shares
A - Award 3,923 3,923
2022-01-03 2021-12-29 4 BBIO BridgeBio Pharma, Inc.
Common Stock
P - Purchase 80,000 88,491 942.17 14.50 1,160,000 1,283,120
2021-07-01 2021-07-01 4 PRAH PRA Health Sciences, Inc.
Common Stock
D - Sale to Issuer -3,521 0 -100.00
2021-06-22 2021-06-17 4 BBIO BridgeBio Pharma, Inc.
Stock Option (right to buy)
A - Award 38,895 38,895
2021-06-03 2021-06-01 4 PRAH PRA Health Sciences, Inc.
Common Stock
A - Award 330 3,521 10.34
2020-11-20 2020-11-20 4 MAAC Montes Archimedes Acquisition Corp
Class B common stock
J - Other -1,232,044 10,167,956 -10.81
2020-06-04 2020-06-02 4 BBIO BridgeBio Pharma, Inc.
Stock Option (right to buy)
A - Award 112,422 112,422
2020-05-20 2020-05-18 4 PRAH PRA Health Sciences, Inc.
Common Stock
A - Award 1,748 3,191 121.14
2020-02-14 2020-02-12 4 BBIO BridgeBio Pharma, Inc.
Stock Option (Right to Buy)
A - Award 24,927 24,927
2020-02-14 2020-02-12 4 BBIO BridgeBio Pharma, Inc.
Common Stock
A - Award 8,491 8,491
2019-12-16 2019-12-12 4 BBIO BridgeBio Pharma, Inc.
Stock Option (right to buy)
A - Award 82,878 82,878
2019-08-15 2019-08-13 4 PRAH PRA Health Sciences, Inc.
Common Stock
A - Award 1,443 1,443
2018-03-01 2018-02-28 4 ENTL ENTELLUS MEDICAL INC
Stock Option (right to buy)
D - Sale to Issuer -7,500 0 -100.00 6.33 -47,475
2018-03-01 2018-02-28 4 ENTL ENTELLUS MEDICAL INC
Common Stock, $0.001 par value
D - Sale to Issuer -3,750 0 -100.00 24.00 -90,000
2017-07-18 2017-07-14 4 ENTL ENTELLUS MEDICAL INC
Stock Option (right to buy)
A - Award 7,500 7,500
2017-07-18 2017-07-14 4 ENTL ENTELLUS MEDICAL INC
Common Stock, $0.001 par value
A - Award 3,750 3,750
2017-07-18 3 ENTL ENTELLUS MEDICAL INC
Common Stock, $0.001 par value
0
2013-08-14 2013-08-13 4 JAZZ Jazz Pharmaceuticals plc
Ordinary Shares
S - Sale -1,070 17,315 -5.82 81.86 -87,590 1,417,406
2013-08-12 2013-08-08 4 JAZZ Jazz Pharmaceuticals plc
Nonstatutory Stock Option (right to buy)
A - Award 4,500 4,500
2013-08-12 2013-08-08 4 JAZZ Jazz Pharmaceuticals plc
Ordinary Shares
A - Award 2,250 18,385 13.94
2012-08-13 2012-08-09 4 JAZZ Jazz Pharmaceuticals plc
Option (right to buy)
A - Award 4,500 4,500
2012-08-13 2012-08-09 4 JAZZ Jazz Pharmaceuticals plc
Ordinary Shares
A - Award 2,250 16,135 16.20
2012-03-15 3/A JAZZ Jazz Pharmaceuticals plc
Ordinary Shares
13,885
2012-03-15 2012-01-18 4/A JAZZ Jazz Pharmaceuticals plc
Phantom Stock
D - Sale to Issuer 17,507 0 -100.00
2012-03-15 2012-01-18 4/A JAZZ Jazz Pharmaceuticals plc
Common Stock
D - Sale to Issuer -13,885 0 -100.00
2012-01-19 3 JAZZ Jazz Pharmaceuticals plc
Common Stock
13,885
2012-01-18 2012-01-18 4 JAZZ Jazz Pharmaceuticals plc
Phantom Stock
D - Sale to Issuer 16,792
2012-01-18 2012-01-18 4 JAZZ Jazz Pharmaceuticals plc
Common Stock
D - Sale to Issuer -13,885 0 -100.00
2012-01-13 2012-01-11 4 JAZZ JAZZ PHARMACEUTICALS INC
Option (right to buy)
M - Exercise -12,500 0 -100.00
2012-01-13 2012-01-11 4 JAZZ JAZZ PHARMACEUTICALS INC
Option (right to buy)
M - Exercise -12,500 0 -100.00
2012-01-13 2012-01-11 4 JAZZ JAZZ PHARMACEUTICALS INC
Common Stock
F - Taxes -8,999 13,885 -39.32 48.60 -437,351 674,811
2012-01-13 2012-01-11 4 JAZZ JAZZ PHARMACEUTICALS INC
Common Stock
M - Exercise 12,500 22,884 120.38 34.99 437,375 800,711
2012-01-13 2012-01-11 4 JAZZ JAZZ PHARMACEUTICALS INC
Common Stock
F - Taxes -2,116 10,384 -16.93 48.60 -102,838 504,662
2012-01-13 2012-01-11 4 JAZZ JAZZ PHARMACEUTICALS INC
Common Stock
M - Exercise 12,500 12,500 8.23 102,875 102,875
2006-11-29 2006-11-29 4 AIQ ALLIANCE IMAGING INC /DE/
Common Stock
S - Sale -1,200,000 25,944,570 -4.42 5.40 -6,486,000 140,230,401
2006-11-29 2006-11-27 4 AIQ ALLIANCE IMAGING INC /DE/
Common Stock
S - Sale -8,000,000 27,144,570 -22.76 5.40 -43,240,000 146,716,401
2005-10-14 2005-10-12 4 ACW ACCURIDE CORP
Common Stock
S - Sale -641,137 7,850,213 -7.55 13.25 -8,495,065 104,015,322
2005-10-07 2005-10-05 4 ACW ACCURIDE CORP
Common Stock
S - Sale -4,274,250 8,491,350 -33.48 13.25 -56,633,812 112,510,388
2005-04-25 3 ACW ACCURIDE CORP
Common Stock
12,765,600
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)